PPT: Hydroxychloroquine Market to Witness Huge Growth during 2021-2026

1
Global Hydroxychloroquine Market Research and
Forecast Report 2021-2026




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Hydroxychloroquine Market Research
Report According to the latest report by IMARC
Group, titled "Hydroxychloroquine Market Global
Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2021-2026," the global
hydroxychloroquine market reached a strong growth
in 2020.  Hydroxychloroquine (HCQ) is a
derivative of chloroquine with the chemical
formula C18H26ClN3O. It is a chemotherapeutic
agent drug that was primarily used to suppress
and treat acute attacks of malaria. It is widely
known to be effective against the erythrocytic
forms of malarial parasites. Apart from this, it
is extensively utilized for the treatment of
numerous autoimmune conditions. For instance, it
is used for alleviating skin problems in lupus as
well as avoiding pain or swelling caused due to
arthritis. It is also being employed as a
possible treatment of the rapidly spreading
coronavirus disease (COVID-19) due to the
immunosuppressive, anti-autophagy and
antimalarial properties offered by the
drug. Request Free Sample Report
https//www.imarcgroup.com/hydroxychloroquine-mark
et/requestsample
4
Report Description and Highlights
Report Description
Global Hydroxychloroquine Market Trends The
market is primarily driven by the rapid outbreak
of COVID-19 across the globe. Since HCQ is widely
being used as a potential treatment of the same,
numerous clinical trials and experiments are
currently underway to determine the efficacy of
the drug against the virus. The results of these
trials are expected to ascertain the positive
demand for the drug on the global level. Apart
from this, the increasing occurrence of malaria
and various other chronic diseases across
developing and underdeveloped countries are
expected to provide an impetus to the market
growth. The market is further driven by the
growing incidences of autoimmune diseases, such
as lupus erythematosus and rheumatoid arthritis,
among individuals. This, along with the growing
population and increasing health awareness amid
masses, is anticipated to boost the uptake of
HCQ. Extensive research and development (RD)
activities are also being conducted by several
players in the field of medical sciences. This,
coupled with the rising healthcare spending by
several governments and the implementation of
favorable government policies to promote global
health, is expected to create a positive outlook
for the market. Looking forward, the market
value is projected to reach a strong growth
during the forecast period (2021-2026).

5
Report Description and Highlights
Report Description

• Market Summary
• Breakup by Dosage Type
• 200 Mg
• 300 Mg
• 400 Mg
• Others
•  
• Breakup by Distribution
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Breakup by Application
• Rheumatoid Arthritis
• Lupus Erythematosus
• Malaria
• Coronavirus (COVID-19)
• Others

6
Report Description and Highlights
Report Description

• Breakup by Grade
• USP Standards Grade
• EP Standards Grade
• Pharmaceutical Standards Grade
• Others
• Breakup by Route of Administration
• Oral
• Intravenous
• Breakup by Region
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea

7
Report Description and Highlights
Report Description

• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Argentina
• Columbia
• Chile
• Peru
• Others
• Others

8
Report Description and Highlights
Report Description

• Middle East and Africa Turkey
• Saudi Arabia
• Iran
• United Arab Emirates
• Note We are updating our reports, If you want
  latest primary and secondary data (2021-2026)
  with Cost Module, Business Strategy, Distribution
  Channel, etc. Click request free sample report.
• Competitive Landscape with Key Players
• Amneal Pharmaceuticals Inc.
• Cardinal Health Inc.
• Cipla Ltd.
• Ipca Laboratories Ltd.
• Laurus Labs
• Lupin Limited
• Mylan N.V.
• Novartis AG
• Prasco Laboratories
• Dr. Reddys Laboratories Ltd.
• Sanofi S.A.

9
Report Description and Highlights
Report Description

• Teva Pharmaceutical Industries Ltd.
• Torrent Pharma
• Zydus Cadila,
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/hydroxychloroquine-mark
  et

10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
12
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
13

Contact Us